In Segment C, members will receive ABBV-744 and oral navitoclax. In Segment D, participants will acquire ABBV-744 and ruxolitinib. Contributors will acquire treatment until eventually disease progression or the participants are unable to tolerate the study drugs. 88 These preclinical studies deliver paradigms for foreseeable future clinical trials in AML, https://nealey111kwh3.wikissl.com/user